Real-World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction.

In our dataset, trends in these factors were observed (e.g., numerically higher response rates in females and in those with baseline SALT < 95), but they did not reach statistical significance, potentially due to limited sample size or confounding.

also in 111,027 other papers